Aqemia is a next-gen pharmatech company focused on drug discovery using quantum-inspired physics algorithms to power generative AI. The company designs innovative drug candidates for critical diseases like immuno-oncology without relying on experimental data, achieving several successes internally and through collaborations. Aqemia is part of the French Tech 120 program and has offices in Paris and London.
AQEMIA is building a new generation of AI-driven drug discovery workflows, and this role is critical to scaling the speed and reliability of our pre-program screening operations. As Computational Chemist – Pre-Programs, you will own the end-to-end execution and monitoring of QEMI virtual screening and hit expansion campaigns, from structure selection and target preparation to active hit selection.
Aqemia is a next-gen pharmatech company focused on drug discovery using quantum-inspired physics algorithms to power generative AI. The company designs innovative drug candidates for critical diseases like immuno-oncology without relying on experimental data, achieving several successes internally and through collaborations. Aqemia is part of the French Tech 120 program and has offices in Paris and London.